OX40 Monoclonal Antibody (7D6), FITC, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA516547-Each-of-1 | In Stock | ₹ 63,635.00 |
PIMA516547 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 63,635.00
GST (18%): ₹ 11,454.30
Total Price: ₹ 75,089.30
Antigen
OX40
Classification
Monoclonal
Concentration
0.1 mg/mL
Formulation
PBS with 1% BSA and 0.09% sodium azide
Gene Accession No.
P43489
Gene Symbols
Tnfrsf4
Immunogen
CHO-derived feline CD134-Fc fusion protein.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Feline, Human
Product Type
Antibody
Isotype
IgG1
Applications
Flow Cytometry
Clone
7D6
Conjugate
FITC
Gene
Tnfrsf4
Gene Alias
ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l
Host Species
Mouse
Purification Method
Protein G
Regulatory Status
RUO
Gene ID (Entrez)
493665, 7293
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. Store in the dark.
Form
Liquid
Related Products
Description
- This antibody does not react with mouse
- For FACS analysis, use 10 μL of the suggested working dilution to label 1x10^6 cells in 100 μL
- OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system
- When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents
- OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer
- They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.